{"version":"1.0","type":"link","title":"BOS172738, a selective RET inhibitor, for the treatment of patients with RET-altered tumors including RET-fusion-positive non-small-cell lung cancer and RET-mutant medullary thyroid cancer: a phase I dose-escalation/expansion multicenter study.","author_name":"Schöffski P 외","author_url":"https://prs-insight.online/author/Sch%C3%B6ffski%20P","provider_name":"PRSinsight","provider_url":"https://prs-insight.online","thumbnail_url":"https://prs-insight.online/og/paper/140221","thumbnail_width":1200,"thumbnail_height":630}